{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T14:39:36Z","timestamp":1774795176165,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,15]]},"DOI":"10.1093\/infdis\/jiw597","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T09:34:31Z","timestamp":1483954471000},"page":"599-605","source":"Crossref","is-referenced-by-count":22,"title":["TURQUOISE-I Part 1b: Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir"],"prefix":"10.1093","volume":"215","author":[{"given":"David","family":"Wyles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Saag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando M.","family":"Viani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwatoyin","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laveeza","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran B.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy S.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ruane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"key\n\t\t\t\t20170330133449_CIT0001","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.antiviral.2009.10.021","article-title":"Viral hepatitis and HIV co-infection","volume":"85","year":"2010","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20170330133449_CIT0002","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study","volume":"166","year":"2006","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170330133449_CIT0003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","year":"2006","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170330133449_CIT0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170330133449_CIT0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","year":"2013","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170330133449_CIT0006","first-page":"370","article-title":"Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV\/HCV","volume":"308","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170330133449_CIT0007","volume-title":"VIEKIRA PAK (ombitasvir, paritaprevir\/ritonavir, dasabuvir) prescribing information","year":"2015"},{"key":"key\n\t\t\t\t20170330133449_CIT0008","volume-title":"EXVIERA (dasabuvir) summary of product characteristics","year":"2015"},{"key":"key\n\t\t\t\t20170330133449_CIT0009","volume-title":"VIEKIRAX (ombitasvir, paritaprevir\/ritonavir) summary of product characteristics","year":"2015"},{"key":"key\n\t\t\t\t20170330133449_CIT0010","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170330133449_CIT0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","article-title":"Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial","volume":"14","year":"2013","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170330133449_CIT0012","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","article-title":"Week 48 analysis of once-daily vs. twice-daily darunavir\/ritonavir in treatment-experienced HIV-1-infected patients","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170330133449_CIT0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"TITAN Study Group","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170330133449_CIT0014","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/civ1213","article-title":"Evaluation of drug-drug interactions between hepatitis c antiviral agents ombitasvir, paritaprevir\/ritonavir, and dasabuvir and HIV-1 protease inhibitors","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170330133449_CIT0015","volume-title":"Prezista (darunavir) package insert","author":"Janssen Pharmaceuticals I","year":"2015"},{"key":"key\n\t\t\t\t20170330133449_CIT0016","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170330133449_CIT0017","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170330133449_CIT0018","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170330133449_CIT0019","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/infdis\/jis104","article-title":"Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis","volume":"205","author":"CANOC Collaboration","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170330133449_CIT0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jama.293.7.817","article-title":"Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART","volume":"293","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170330133449_CIT0021","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170330133449_CIT0022","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/infdis\/jis109","article-title":"More reasons to reexamine the definition of viral blip during antiretroviral therapy","volume":"205","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170330133449_CIT0023","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/jac\/dku516","article-title":"Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial","volume":"70","author":"DRV600 Study Group","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170330133449_CIT0024","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/jac\/dkq150","article-title":"Suboptimal adherence to darunavir\/ritonavir has minimal effect on efficacy compared with lopinavir\/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data","volume":"65","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/215\/4\/599\/11147487\/jiw597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:33:21Z","timestamp":1658363601000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jiw597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,3,14]]},"published-print":{"date-parts":[[2017,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiw597","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]}}}